GleamWall
中文EN

ELOX Eloxx Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1035354 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.6%
ROA-27.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.17x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312023Q4*2023-12-31
Income statement
Revenue————————
R&D expense$4.03M$2.84M$1.66M$1.90M-$250,000$898,000$510,000$1.52M
SG&A expense$1.93M$1.61M$2.14M$1.45M$535,000$684,000$712,000$2.51M
Operating income-$5.95M-$4.45M-$3.79M-$3.35M-$285,000-$1.58M-$1.22M-$4.03M
Interest expense$100,000$100,000$100,000—$200,000$300,000$500,000—
Net income-$5.54M-$4.50M-$3.75M-$2.04M-$351,000-$1.89M-$1.71M-$2.89M
EBITDA———————-$3.96M
EPS (basic)-0.49-0.66-0.08—-0.58-5.45-0.45—
EPS (diluted)-0.49-0.66-0.08—-0.58-5.45-0.45—
Weighted avg. shares (diluted)11.40M6.79M48.21M—604,278347,0003.81M—
Balance sheet
Cash & equivalents$56.26M$61.96M$6.36M$4.79M$4.21M$572,000$450,000$1.13M
Current assets$58.26M$63.39M$8.50M$5.27M———$1.55M
PP&E, net———$0———$35,000
Total assets$58.26M$63.39M$8.50M$5.27M———$1.71M
Current liabilities$17.19M$16.97M$16.09M$17.18M———$22.70M
Short-term debt$0$0$0$1.00M———$2.22M
Long-term debt———$0———$1.61M
Total debt———$1.00M———$3.83M
Total liabilities$17.19M$16.97M$16.09M$17.18M———$24.31M
Shareholders' equity$41.07M$46.42M-$7.58M-$11.91M-$14.99M-$27.90M-$26.02M-$22.60M
Net debt———-$3.79M———$2.70M
Shares outstanding4.09M4.04M5.07M435,432———3.14M
Cash flow statement
Operating cash flow-$4.28M-$4.79M-$5.45M-$4.06M-$1.72M-$1.75M$1.20M-$2.01M
Investing cash flow———————$51,000
Financing cash flow-$1.42M$60.39M$7.03M$4.64M$5.35M$1.88M-$865,000-$1.68M
Depreciation & amortization———————$73,000
Stock-based compensation$190,000$95,000$46,000$189,000$10,000$16,000$20,000$340,000

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.